TY - JOUR T1 - Chloroquine Administration in Breastfeeding Mothers Associates with Increased HIV-1 Plasma Viral Loads JF - medRxiv DO - 10.1101/2020.04.29.20085308 SP - 2020.04.29.20085308 AU - William A Paxton AU - Marloes A Naarding AU - Ferdinand WNM Wit AU - Nienke J Veldhuijzen AU - Matthew F Chersich AU - Brigitte Kankindi AU - Rene A Douma AU - Samuel Tuyizere AU - Suzanne Jurriaans AU - Rolf W Sparidans AU - Jos H Beijnen AU - Georgios Pollakis AU - Johan R Boelaert AU - Joep MA Lange AU - Joseph Vyankandondera AU - Stanley Luchters Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085308.abstract N2 - Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been proposed to be effective at treating COVID-19 patients. We, and others, have previously reported on the capacity of CQ to reduce HIV-1 replication in vitro. We tested CQ administration in post-partum mothers on influencing HIV-1 viral loads in human milk as a means of lowering mother to child transmission. A Phase I/II, randomized, placebo-controlled study to evaluate chloroquine administration to reduce HIV-1 RNA levels in human milk: the CHARGE study. Thirty HIV-1 positive pregnant Rwandese women (CQ n = 20; placebo n = 10) were enrolled in a 16-week study, with the treatment group receiving a 200 mg oral dose of CQ daily. Base-line plasma viral load (pVL) measurements and CD4 counts were determined prior to delivery, and pVL, breast milk VL (bmVL) and CQ levels measured during treatment. For women receiving treatment, CQ concentration was higher in breast milk compared to plasma (over 2.5-fold), with a positive correlation between the levels in the two compartments (P < 0.003). A link between high CQ concentrations in plasma and high CD4 counts (P < 0.001) was observed. Surprisingly, we found a significant increase in pVL after CQ treatment in over half of the mothers (n=11; P < 0.001) and with no alteration to bmVL measurements. No specific amino acid alterations in the gp120 envelope sequences could be associated with CQ administration. CQ usage is associated with a significant increase to pVL in early breastfeeding mothers from Rwanda which cautions against the use of CQ in such individuals. Our results highlight a discrepancy between CQ effects on modulating HIV-1 replication in vitro versus in vivo and indicate caution when prescribing CQ to post-partum HIV-1 untreated mothers. This discrepancy should be taken into consideration when testing CQ or HCQ treatment in COVID-19 clinical trials, especially relating to the post-partum setting.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSTEG-METC (ref no R01-089)Funding StatementThis work was supported through Dutch AIDS Funds (6013) and Elizabeth Glaser Pediatric AIDS Foundation (27-PG-51269).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available ER -